Design of supersaturable formulation of telmisartan with pH modifier: in vitro study on dissolution and precipitation

Journal of Pharmaceutical Investigation - Tập 47 - Trang 163-171 - 2017
Shinji Yamashita1, Arima Fukunishi2, Haruki Higashino1, Makoto Kataoka1, Koichi Wada3
1Faculty of Pharmaceutical Sciences, Setsunan University, Hirakata, Japan
2Takeda Pharmaceutical Co., Ltd., Yodogawa-ku, Japan
3Nippon Boehringer Ingelheim Co., Ltd., Chuo-ku, Kobe, Japan

Tóm tắt

Telmisartan is a biopharmaceutics drug classification system class II drug having a low solubility at neutral pH region. The purpose of this study is to clarify the process of dissolution and precipitation of telmisartan in the gastrointestinal tract from its oral formulation containing meglumine, a pH modifier (alkalizer). Granules of telmisartan containing different amount of meglumine were prepared, and its dissolution and precipitation profiles were investigated under various pH conditions in vitro. It was demonstrated that meglumine induced a supersaturation of telmisartan both at pH 5.0 and pH 6.8. Dissolved amount of telmisartan fluctuated over time and the pattern of dissolved concentration differed depending on the pH and the amount of meglumine. Powder X-ray diffraction analysis and differential scanning calorimetry analysis on precipitates from supersaturated solutions showed that pH of the dissolution medium profoundly affects the crystalline form of telmisartan. Furthermore, the effect of meglumine on oral absorption of telmisartan was investigated with dissolution/permeation System in vitro. At pH 6.8, permeated amount was significantly higher with the formulation which contains larger amount of meglumine. Therefore, despite the very low solubility of telmisartan at neutral pH, meglumine significantly provided high solubility of telmisartan by induction and maintenance of its supersaturation.

Tài liệu tham khảo

Buch P, Langguth P, Kataoka M, Yamashita S (2008) IVIVC in oral absorption for fenofibrate immediate release tablets using a dissolution / permeation system. J Pharm Sci 98(6):2001–2009 Carlert S, Pålsson A, Hanisch G, Corswant C, Nilson C, Lindfors L, Lennernäs H, Abrahamsson B (2010) Prediction intestinal precipitation—a case example for a basic BCS class II drug. Pharm Res 27:2119–2130 Chowhan ZT (1978) pH-Solubility profiles of organic carboxylic acids and their salts. J Pharm Sci 67:1257–1260 Dressman JB, Berardi RR, Dermetzoglou LC, Russell T, Schmaltz SP, Barnett JL, Jarvenpaa KM (1990) Upper gastrointestinal (GI) pH in young, healthy men and women. Pharm Res 7:756–761 Guideline for Bioequivalence Studies of Generic Products (2012) Attachment 1 of Division Notification 0229 No.10 of the Pharmaceutical and Food Safety Bureau Japan Higashino H, Hasegawa T, Yamamoto M, Matsui R, Masaoka Y, Kataoka M, Sakuma S, Yamashita S (2014) In vitro-in vivo correlation in the effect of supersaturation on intestinal absorption of BCS class 2 drugs. Mol Pharm 11(3):746–754 Hisada N, Takano R, Takata N, Shiraki K, Ueto T, Tanida S, Kataoka M, Yamashita S (2016) Characterizing the dissolution profiles of supersaturable salts, cocrystals, and solvates to enhance in vivo oral absorption. Eur J Pharm Biopharm 103:192–199 Kalantzi L, Goumas K, Kalioras V, Abrahamsson B, Dressman JB, Reppas C (2006) Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability / bioequivalence studies. Pharm Res 23:165–176 Kataoka M, Takashima T, Shingaki T, Hashidzume Y, Katayama Y, Wada Y, Oh H, Masaoka Y, Sakuma S, Sugiyama Y, Yamashita S, Watanabe Y (2012) Dynamic analysis of GI absorption and hepatic distribution processes of telmisartan in rats using positron emission tomography. Pharm Res 29(9):2419–2431 Kataoka M, Yano K, Hamatsu Y, Masaoka Y, Sakuma S, Yamashita S (2013) Assessment of absorption potential of poorly water-soluble drugs by using the dissolution/permeation system. Eur J Pharm Biopharm 85(3):1317–1324 Kleppe MS, Forney-Stevens KM, Haskell RJ, Bogner RH (2015) Mathematical Models to explore potential effects of supersaturation and precipitation on oral bioavailability of poorly soluble drugs. AAPS J 17(4):902–917 Kramer SF, Flynn GL (1972) Solubility of organic hydrochlorides. J Pharm Sci 61:1896–1904 Ovesen L, Bendtsen F, Tage-Jensen U, Pedersen NT, Gram BR, Rune SJ (1986) Intraluminal pH in the stomach, duodenum and proximal jejunum in normal subjects and patients with exocrine pancreatic insufficiency. Gastroenterology 90:958–962 Ozaki S (2011) Supersaturation-nucleation behavior of poorly soluble drugs and its impact on the oral absorption of drugs in thermodynamically high-energy forms. J Pharm Sci 101(1):214–222 Sharpe M, Jarvis B, Goa KL (2001) Telmisartan: a review of its use in hypertension. Drugs 61:1501–1529 Smith DHC, Matzek KM, Kempthorne-Rawson J (2000) Dose response and safety of telmisartan in patient with mild to moderate hypertension. J Clin Pharmacol 40:1380–1390 Staingier J, Chung-An PF Su CA, Schöndorfer G, Roth W (2000b) Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers. J Clin Pharmacol 40:1355–1364 Stangier J, Su CA, Roth W (2000a) Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 28:149–167 Sugano K (2009) Introduction to computational oral absorption simulation. Expert Opin 5:259–293 Takano R, Takata N, Saito R, Furumoto K, Higo S, Hayashi Y, Machida M, Aso Y, Yamashita S (2010) Quantitative analysis of the effect of supersaturation on in vivo drug absorption. Mol Pharm 7(5):1431–1440 Tatami S, Rarashina A, Yamamura N, Igarashi T (2003) Population pharmacokinetics of an angiotensin II receptor antagonist, telmisartan, in healthy volunteers and hypertension patients. Drug Metab Pharmacokin 18:203–211 Ueda K, Higashi K, Kataoka M, Yamashita S, Yamamoto K, Moribe K (2014) Inhibition mechanism of hydroxypropyl methylcellulose acetate succinate on drug crystallization in gastrointestinal fluid and drug permeability from a supersaturated solution. Eur J Pharm Sci 62:293–300 Wienen W, Entzeroth M, Meel JCA, Stangier J, Busch U, Ebner T, Schmid J, Lehmann H, Matzek K, Kempthorne-Rawson J, Glagigau V, Hauel NH (2000) A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist. Cardiovasc Drug Rev 18(2):127–154 The Japanese Pharmacopoeia seventeenth edition (2016)